
Calliditas Therapeutics AB
STO:CALTX


to continue CALTX research
to continue CALTX research
You've reached your weekly stock limit.
Sign UpCalliditas Therapeutics AB?
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
Energy
|
We'll email you a reminder when the closing price reaches USD.
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
205.4
208
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.

What unique competitive advantages
does Calliditas Therapeutics AB hold over its rivals?
What risks and challenges
does Calliditas Therapeutics AB face in the near future?
Is it considered overvalued or undervalued
based on the latest financial data?
Provide an overview of the primary business activities
of Calliditas Therapeutics AB.
Provide an overview of the primary business activities
of Calliditas Therapeutics AB.
What unique competitive advantages
does Calliditas Therapeutics AB hold over its rivals?
What risks and challenges
does Calliditas Therapeutics AB face in the near future?
Has there been any significant insider trading activity
in Calliditas Therapeutics AB recently?
Summarize the latest earnings call
of Calliditas Therapeutics AB.
Is it considered overvalued or undervalued
based on the latest financial data?
Show all valuation multiples
for Calliditas Therapeutics AB.
Provide P/S
for Calliditas Therapeutics AB.
Provide P/E
for Calliditas Therapeutics AB.
Provide P/OCF
for Calliditas Therapeutics AB.
Provide P/FCFE
for Calliditas Therapeutics AB.
Provide P/B
for Calliditas Therapeutics AB.
Provide EV/S
for Calliditas Therapeutics AB.
Provide EV/GP
for Calliditas Therapeutics AB.
Provide EV/EBITDA
for Calliditas Therapeutics AB.
Provide EV/EBIT
for Calliditas Therapeutics AB.
Provide EV/OCF
for Calliditas Therapeutics AB.
Provide EV/FCFF
for Calliditas Therapeutics AB.
Provide EV/IC
for Calliditas Therapeutics AB.
Show me price targets
for Calliditas Therapeutics AB made by professional analysts.
What are the Revenue projections
for Calliditas Therapeutics AB?
How accurate were the past Revenue estimates
for Calliditas Therapeutics AB?
What are the Net Income projections
for Calliditas Therapeutics AB?
How accurate were the past Net Income estimates
for Calliditas Therapeutics AB?
What are the EPS projections
for Calliditas Therapeutics AB?
How accurate were the past EPS estimates
for Calliditas Therapeutics AB?
What are the EBIT projections
for Calliditas Therapeutics AB?
How accurate were the past EBIT estimates
for Calliditas Therapeutics AB?
Compare the revenue forecasts
for Calliditas Therapeutics AB with those of its competitors based on recent analyst estimates.
Compare the intrinsic valuations
of Calliditas Therapeutics AB and its key competitors using the latest financial data.
Compare historical revenue growth rates
of Calliditas Therapeutics AB against its competitors.
Analyze the profit margins
(gross, operating, and net) of Calliditas Therapeutics AB compared to its peers.
Compare the P/E ratios
of Calliditas Therapeutics AB against its peers.
Discuss the investment returns and shareholder value creation
comparing Calliditas Therapeutics AB with its peers.
Analyze the financial leverage
of Calliditas Therapeutics AB compared to its main competitors.
Show all profitability ratios
for Calliditas Therapeutics AB.
Provide ROE
for Calliditas Therapeutics AB.
Provide ROA
for Calliditas Therapeutics AB.
Provide ROIC
for Calliditas Therapeutics AB.
Provide ROCE
for Calliditas Therapeutics AB.
Provide Gross Margin
for Calliditas Therapeutics AB.
Provide Operating Margin
for Calliditas Therapeutics AB.
Provide Net Margin
for Calliditas Therapeutics AB.
Provide FCF Margin
for Calliditas Therapeutics AB.
Show all solvency ratios
for Calliditas Therapeutics AB.
Provide D/E Ratio
for Calliditas Therapeutics AB.
Provide D/A Ratio
for Calliditas Therapeutics AB.
Provide Interest Coverage Ratio
for Calliditas Therapeutics AB.
Provide Altman Z-Score Ratio
for Calliditas Therapeutics AB.
Provide Quick Ratio
for Calliditas Therapeutics AB.
Provide Current Ratio
for Calliditas Therapeutics AB.
Provide Cash Ratio
for Calliditas Therapeutics AB.
What is the historical Revenue growth
over the last 5 years for Calliditas Therapeutics AB?
What is the historical Net Income growth
over the last 5 years for Calliditas Therapeutics AB?
What is the current Free Cash Flow
of Calliditas Therapeutics AB?
Discuss the annual earnings per share (EPS)
trend over the past five years for Calliditas Therapeutics AB.
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
SE |
![]() |
Calliditas Therapeutics AB
STO:CALTX
|
12.5B SEK | -35.9 | |
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
754.1B USD | 36.4 |
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 3 846.3 |
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
367.2B USD | 12.3 |
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK | 12.7 |
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
208.9B CHF | 9.5 |
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
188.5B CHF | 10.7 |
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
157.3B GBP | 130.6 |
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
199.7B USD | 8.5 |
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD | 261.3 |
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
137.9B USD | 7.5 |
|
EBITDA Growth | EV/EBITDA to Growth | |||||
---|---|---|---|---|---|---|
SE |
![]() |
Calliditas Therapeutics AB
STO:CALTX
|
Average EV/EBITDA:
433.6
|
N/A | N/A | |
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
36.4
|
30%
|
1.2 |
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
3 846.3
|
36%
|
106.8 |
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
12.3
|
7%
|
1.8 |
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
12.7
|
13%
|
1 |
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
9.5
|
5%
|
1.9 |
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
10.7
|
5%
|
2.1 |
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
130.6
|
10%
|
13.1 |
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
8.5
|
8%
|
1.1 |
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
261.3
|
N/A | N/A |
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
7.5
|
2%
|
3.8 |
|
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.